- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07835113
Tissue Sensor for Semirigid Thulium Fiber Laser Ureterolithotripsy (Tissue Sensor)
Tissue Sensor to Reduce Laser-Induced Ureteral Injury During Semirigid Thulium Fiber Laser Ureterolithotripsy: The TISSUE Multicenter Randomized Controlled Trial
Tissue Sensor (TS) is a technology designed to automatically deactivate laser emission when contact between the laser fiber and tissue is detected. It is hypothesized that the use of TS during contact laser ureterolithotripsy may reduce unintended laser exposure of the ureteral mucosa, thereby decreasing the risk of immediate thermal injury to the ureteral wall and subsequent scar-related narrowing.
To reduce the influence of baseline risk factors for stricture, the study will enroll a homogeneous population of patients without urinary tract anomalies, previous surgery on the study ureter, or impacted stones. The procedure will be performed according to a standardized protocol using a semirigid ureteroscope, a thulium fiber laser, and predefined technical restrictions. The study is limited to patients with stones in the mid or distal ureter. This approach is intended to minimize the likelihood of stone retropulsion into the kidney, standardize the surgical technique, reduce the need for conversion to flexible ureteroscopy, and maximize comparability between the study groups.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nikita Astakhov
- Phone Number: +8 (968) 490-46-72
- Email: astakhov.nikita@inbox.ru
Study Contact Backup
- Name: Vigen Malkhasyan, Doctor of Medical Sciences
- Phone Number: +79096441688
- Email: botkinhospital@zdrav.mos.ru
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
• Age 18 years or older.
- A single stone in the mid or distal ureter.
- Maximum stone diameter of 15 mm or less on preoperative CT.
- An indication for elective semirigid laser ureterolithotripsy.
- Feasibility of performing the procedure with a semirigid ureteroscope.
- No active urinary tract infection at the time of the intervention.
- Ability to undergo CT follow-up and complete 12 months of follow-up.
- Signed written informed consent.
Exclusion Criteria:
-
• Age 18 years or older.
- A single stone in the mid or distal ureter.
- Maximum stone diameter of 15 mm or less on preoperative CT.
- An indication for elective semirigid laser ureterolithotripsy.
- Feasibility of performing the procedure with a semirigid ureteroscope.
- No active urinary tract infection at the time of the intervention.
- Ability to undergo CT follow-up and complete 12 months of follow-up.
- Signed written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patients after ureterolithotrypsy with Tissue Sensor activated
Semirigid TFL ureterolithotripsy will be performed with Tissue Sensor activated. All automatic system trigger events will be recorded by the laser system or in the study case report form and, whenever possible, synchronized with the procedure video recording |
Semirigid TFL ureterolithotripsy will be performed with Tissue Sensor activated. All automatic system trigger events will be recorded by the laser system or in the study case report form and, whenever possible, synchronized with the procedure video recording |
|
Experimental: Patients after ureterolithotrypsy with Tissue Sensor deactivated
Semirigid TFL ureterolithotripsy will be performed with Tissue Sensor deactivated. Visually confirmed contacts between the activated laser fiber and the ureteral mucosa will be recorded from the procedure video |
Semirigid TFL ureterolithotripsy will be performed with Tissue Sensor deactivated. Visually confirmed contacts between the activated laser fiber and the ureteral mucosa will be recorded from the procedure video. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of intraoperative laser-induced injury to the ureteral mucosa
Time Frame: intraoperative
|
Incidence of intraoperative laser-induced injury to the ureteral mucosa, defined as any visible injury compatible with exposure to an activated laser fiber, as determined by independent blinded video assessment. |
intraoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of postoperative ureteral stricture
Time Frame: 12 months.
|
Incidence of postoperative ureteral stricture detected during the 12 months after the intervention.
|
12 months.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MoscowBotkinHospital2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.